Otolith Labs Unveils Groundbreaking Study Proving Technology’s Ability to Combat Cybersickness in Virtual Reality Experiences

Admin

Updated on:

Otolith Labs Unveils Groundbreaking Study Proving Technology’s Ability to Combat Cybersickness in Virtual Reality Experiences

Original research article published by Frontiers, a top peer-reviewed scientific journal

WASHINGTON, Feb. 13, 2025 /PRNewswire/ — Otolith Labs is at the forefront of medical tech, working on devices to help people with vestibular disorders. They recently shared findings from a study that looked at how vestibular stimulation can ease cybersickness in virtual reality (VR) settings. The results showed that participants using Otolith’s technology experienced less nausea and could enjoy VR for longer periods.

This exciting study suggests that Otolith’s vestibular stimulation technology may effectively combat cybersickness during engaging VR activities.

Didier Depireux, PhD, one of Otolith’s co-founders, mentioned, “Although VR isn’t our main focus, this study helps us understand how visual inputs interact with vestibular function. VR sickness can be predicted and studied, which is valuable for research.”

A closer look at vestibular stimulation and cybersickness. The study was carried out from 2020 to 2021 by Shamus Smith and others at the University of Newcastle. It involved 30 healthy volunteers aged 19 to 37, including 9 women and 21 men. Each person filled out a Motion Sickness Susceptibility Questionnaire, and then they were divided into three groups: one with low stimulation, another with medium stimulation, and a control group with no stimulation device. All participants wore an Oculus VR headset while experiencing a VR roller-coaster simulation.

During the ride, participants from the stimulation groups reported their nausea levels. Afterward, they completed a Motion Sickness Assessment Questionnaire. The control group followed expected patterns in relation to motion sickness, but the groups using Otolith’s device did not report such issues, suggesting that the stimulation helped reduce cybersickness.

“Many Americans struggle with vestibular disorders, and there’s a lack of non-invasive treatment options. Our goal is to create a wearable device that alleviates chronic symptoms so users can maintain their daily activities,” said Jon Akers, Co-Founder and Chief Technology Officer of Otolith.

About Otolith Labs
Otolith Labs aims to develop medical devices that treat vestibular disorders, which affect millions in the U.S. Their patented technology, recognized by the FDA for treating chronic vertigo, uses targeted vibrations to help the inner ear’s sensors. The company is actively conducting clinical trials to evaluate the effectiveness of its solutions.

About the University of Newcastle
Located in Newcastle, New South Wales, Australia, the University of Newcastle has been a pivotal educational institution since 1965. With a commitment to equity, excellence, and sustainability, the university serves over 37,000 students across various disciplines.

Media contact:
Annalise Kelloff
Otolith Labs
[email protected]

SOURCE Otolith Labs

ywAAAAAAQABAAACAUwAOw==



Source link

Otolith Labs